Noah Medical
Noah Medical builds the Galaxy System, a robotic-assisted bronchoscopy platform with proprietary TiLT+ imaging and a single-use disposable scope, sold to U.S. hospitals and health systems for minimally invasive diagnosis of peripheral lung nodules.
- Company typePrivate
- Founded2018
- HeadquartersSan Carlos, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Noah Medical does
Noah Medical is a San Carlos, California-based medical robotics company founded in 2018 by Jian Zhang (formerly employee #2 at Auris Health, acquired by Johnson & Johnson for $5.7B in 2019). The company develops the Galaxy System, a next-generation robotic-assisted bronchoscopy platform intended for early lung cancer detection through minimally invasive navigation to peripheral pulmonary nodules. The platform integrates proprietary TiLT+ Technology (Tool-in-Lesion Tomography), which combines digital tomosynthesis and augmented fluoroscopy to provide real-time lesion localization and quantitative tool-in-lesion confirmation via the StrikePoint feature, along with a single-use disposable bronchoscope and the smallest footprint among marketed robotic bronchoscopy systems.
The Galaxy System received FDA 510(k) clearance (K230612) in March 2023 and is sold as capital equipment to hospitals and healthcare systems, with recurring revenue from single-use disposable bronchoscopes and procedure-specific accessories; CMS awarded Transitional Pass-Through payment status (HCPCS Code C1601) to qualifying single-use pulmonary bronchoscopes effective January 2024. Noah Medical distributes the platform through a direct enterprise field sales motion targeting academic medical centers, tertiary hospitals, and lung cancer screening centers of excellence, supported by a 10,000-square-foot training academy in Sunnyvale, California.
The company has executed more than 10,000 procedures globally (5,000+ in the United States as of March 2025) across named accounts including University of Chicago Medicine, Cleveland Clinic, Inova Fairfax Hospital, CHI Memorial, Prisma Health, Long Island Jewish Medical Center, and Essentia Health, with international use at Macquarie University Hospital (Australia) and Prince of Wales Hospital (Hong Kong). Backed by a $150 million Series B led by SoftBank Vision Fund and Prosperity7 Ventures in April 2023, Noah Medical is using clinical evidence — including the MATCH 2 study (96.7% diagnostic yield) — to drive commercial expansion.
Noah Medical firmographics
Firmographics- Name
- Noah Medical
- Legal name
- Noah Medical Corporation
- Website
- https://noahmed.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Noah Medical builds the Galaxy System, a robotic-assisted bronchoscopy platform with proprietary TiLT+ imaging and a single-use disposable scope, sold to U.S. hospitals and health systems for minimally invasive diagnosis of peripheral lung nodules.
- Ownership category
- akta.pro rank
Noah Medical industry classification
Industry- Product category
- Medical Robotics
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Bronchoscopy & Interventional Pulmonology (HLAKANAJ)
- akta.pro secondary industry
- Lung Cancer Screening & Pulmonary Nodule Clinic (HLAKANAI)
Keywords
Where Noah Medical is headquartered
LocationHeadquarters
- HQ city
- San Carlos
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Noah Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Galaxy System Capital Equipment: Sale of the Galaxy System robotic bronchoscopy platform as capital equipment to healthcare facilities. The system includes integrated imaging, robotic navigation, and software capabilities.
- Single-use Bronchoscope Consumables: Recurring revenue from single-use disposable bronchoscopes used with the Galaxy System. CMS awarded Transitional Pass-Through (TPT) status to qualifying single-use pulmonary bronchoscopes effective January 2024 with HCPCS Code C1601.
- Procedure-specific Accessories: Single-use accessories associated with Galaxy System procedures, including TiLT+ Technology components.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Galaxy System capital equipment for hospitals |
| Unit Pricing | Pay-as-you-go | Single-use bronchoscope disposables |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
Noah Medical product offering
Product offeringCore offering
Noah Medical designs, manufactures, and commercializes the Galaxy System, a robotic-assisted bronchoscopy platform for early lung cancer detection and diagnosis of peripheral pulmonary nodules. The integrated system combines robotic navigation, proprietary TiLT+ imaging technology (integrated tomosynthesis and augmented fluoroscopy), and a single-use disposable bronchoscope, sold as capital equipment to hospitals with recurring revenue from disposable procedure consumables.
Product overview
Noah Medical offers the Galaxy System as its core commercial product, a next-generation robotic-assisted bronchoscopy platform for early lung cancer detection. The system integrates the proprietary TiLT+ Technology (Tool-in-Lesion Tomography) for real-time imaging and tool-in-lesion confirmation, combined with a single-use disposable bronchoscope as an accessory. The Galaxy System represents a unified, fully integrated solution for navigated bronchoscopy, combining robotic navigation, advanced imaging, and disposable tooling in one platform.
Differentiator
Problem solved
Functional benefit
Brands
- Galaxy System: Robotic-assisted bronchoscopy platform with TiLT+ Technology for early lung cancer detection and diagnosis
- Galaxy System
Products and services
- Galaxy System Robotic-assisted bronchoscopy platform designed for early lung cancer detection through minimally invasive peripheral lung navigation. Combines proprietary TiLT+ Technology with integrated tomosynthesis and augmented fluoroscopy, an always-on-camera single-use disposable bronchoscope, and the smallest footprint among robotic lung biopsy systems. Sold as capital equipment to hospitals and healthcare systems.
- Single-use Disposable Bronchoscope (Galaxy Bronchoscope) Single-use, disposable bronchoscope designed for use with the Galaxy System. Features a camera and single LED light integrated into a tip module with a 2.1mm working channel sized to accommodate any off-the-shelf biopsy tool. Reduces cross-contamination risk, eliminates reprocessing time, and improves procedural workflow.
- Procedure-specific Single-use Accessories Single-use accessories used with the Galaxy System during robotic bronchoscopy procedures, including TiLT+ Technology components and other procedural consumables sold on a recurring basis.
Quantifiable outcome
- 96.7% diagnostic yield in MATCH 2 study of 31 patients
- +6 more outcomes
Companies that use Noah Medical
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles2 records
Noah Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
Noah Medical partnerships and signals
Strategic signalScale indicators8 records
Recent moves7 records
Expansion highlights6 records
Noah Medical competitors and assessment
Company assessmentDirect peers
- Intuitive Surgical: Maker of the Ion robotic bronchoscopy platform, the primary direct competitor to Noah Medical's Galaxy System. Intuitive's Ion uses shape-sensing technology for peripheral lung navigation and benefits from the dominant da Vinci installed base, deep hospital relationships, and substantially larger sales infrastructure than Noah Medical.
- Johnson & Johnson (Auris Health / Monarch): Johnson & Johnson acquired Auris Health for $5.7B in 2019 and now sells the Monarch robotic bronchoscopy platform directly competing with Galaxy. Noah Medical's CEO Jian Zhang was employee #2 at Auris before its acquisition, and J&J's vast medtech commercial footprint makes Monarch a formidable entrenched competitor in the same accounts Noah targets.
Broad incumbents
- Olympus Corporation: Long-standing leader in flexible bronchoscopy and respiratory endoscopy, with broad hospital relationships and a comprehensive reusable bronchoscope portfolio. Olympus is not a direct robotic competitor but its installed base of conventional bronchoscopy systems serves as the workflow reference point hospitals compare robotic platforms against.
- Boston Scientific: Major interventional pulmonology and endoscopy player with products used in lung biopsy procedures, including endobronchial ultrasound (EBUS) and ablation technologies. While not offering a direct robotic bronchoscopy platform, Boston Scientific competes for share-of-wallet in the same interventional pulmonology suites Noah Medical targets.
- Medtronic: Large medtech incumbent with a respiratory and lung health portfolio, including navigated bronchoscopy solutions (via the superDimension acquisition). Medtronic competes broadly in lung cancer diagnostics and could expand its robotic bronchoscopy presence, making it a relevant adjacent competitor.
- Philips: Major imaging and bronchoscopy equipment provider, with strong relationships in pulmonology suites and C-arm fluoroscopy systems that Noah's TiLT+ Technology depends on. Philips competes broadly in the procedural imaging ecosystem that Noah integrates into.
- Fujifilm Healthcare: Provider of flexible bronchoscopes and endoscopy equipment used in pulmonology suites globally. Fujifilm's installed base of reusable bronchoscopes represents the incumbent workflow that robotic platforms like Galaxy must displace or complement in hospital accounts.
- Karl Storz: Established manufacturer of rigid and flexible endoscopes including bronchoscopes and visualization systems used in interventional pulmonology. Karl Storz competes in the broader endoscopy ecosystem that hospitals consider when evaluating robotic bronchoscopy investments.
Emerging players
- Body Vision Medical: Developer of the LungVision platform for real-time intraoperative imaging during bronchoscopy procedures. As a smaller, navigation-focused company, Body Vision targets the same peripheral lung nodule biopsy use case with an alternative approach to tool-in-lesion confirmation.
Others
- Siemens Healthineers: Major C-arm fluoroscopy equipment provider whose hardware is required to operate Noah Medical's TiLT+ Technology. Siemens is both an ecosystem enabler for Galaxy procedures and a potential competitor if it expands into integrated robotic bronchoscopy imaging workflows. Noah's VP of Sales previously held senior roles at Siemens Healthineers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Noah Medical social profiles
Digital presenceNoah Medical compliance and trust
Trust signalCompliance1 record
Noah Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Noah Medical leadership team
Management profileNumber of profiles
Profiles7 records
Noah Medical funding detail
Funding detailFunding overview
Funding rounds2 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Noah Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Noah Medical
What does Noah Medical do?
Noah Medical designs, manufactures, and commercializes the Galaxy System, a robotic-assisted bronchoscopy platform for early lung cancer detection and diagnosis of peripheral pulmonary nodules. The integrated system combines robotic navigation, proprietary TiLT+ imaging technology (integrated tomosynthesis and augmented fluoroscopy), and a single-use disposable bronchoscope, sold as capital equipment to hospitals with recurring revenue from disposable procedure consumables.
Is Noah Medical a public or private company?
Noah Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Noah Medical founded?
Noah Medical was founded in 2018. It employs 251 to 500 people.
Where is Noah Medical based?
Noah Medical is headquartered in San Carlos, United States, in the North America region.
How does Noah Medical make money?
Three revenue lines are on record. Galaxy System Capital Equipment is the primary driver. The others are single-use Bronchoscope Consumables and procedure-specific Accessories.
Who are Noah Medical's main competitors?
Direct peers on record are Intuitive Surgical and Johnson & Johnson (Auris Health / Monarch). Broad incumbents are Olympus Corporation, Boston Scientific, Medtronic, Philips, Fujifilm Healthcare and Karl Storz. Body Vision Medical is listed as an emerging player. Siemens Healthineers is listed as an others.
Does Noah Medical have an API?
No public API is recorded for Noah Medical.
What industry is Noah Medical in?
Noah Medical's product category is Medical Robotics. Its primary akta.pro industry code is HLAKANAJ, Bronchoscopy & Interventional Pulmonology, with a secondary code of HLAKANAI, Lung Cancer Screening & Pulmonary Nodule Clinic. Its NAICS code is 3391 and its SIC code is 3841.